Drugmakers are lowering prices of 10 of the costliest drugs under Medicare, the agency announced last week.
The changes are part of the government’s first-ever negotiations aimed at lowering the price of some of the most expensive and most frequently dispensed drugs under the Medicare program.The changes are part of the government’s first-ever negotiations aimed at lowering the price of some of the most expensive and most frequently dispensed drugs under the Medicare program. The medications are used to treat conditions such as heart disease, diabetes, and cancer.across the 10 drugs.
The savings won’t be seen immediately, however. The new prices won’t go into effect for people with Medicare Part D prescription drug coverage until Jan. 1, 2026. After that, negotiations for 15 other drugs will start with any changes taking place in 2027. More drugs will added each year, the agency said.
Farxiga, a drug for diabetes, heart failure and chronic kidney disease from AstraZeneca, new price $178, down from $556Imbruvica, a drug for blood cancers from AbbVie and Johnson & Johnson, new price $9,319, down from $14,934Jardiance, a diabetes drug from Eli Lily and Boehringer Ingelheim, new price $197, down from $573
Stelara, a drug for psoriasis and Crohn’s disease from J&J, new price $4,695 negotiated price, down from $13,836The new costs do not represent a direct comparison between the negotiated prices and what Medicare and enrollees would have originally paid,The list price is the full price of a medication and doesn’t include rebates or discounts a drug company offers.If you purchase a product or register for an account through a link on our site, we may receive compensation.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Healthy Returns: What drugmakers are saying about final negotiated prices with MedicareDrugmakers appear to be less concerned about the impact of negotiated prices on their businesses in the short term. Meanwhile, health care heads to Hollywood.
Read more »
Healthy Returns: What drugmakers are saying about final negotiated prices with MedicareDrugmakers appear to be less concerned about the impact of negotiated prices on their businesses in the short term. Meanwhile, health care heads to Hollywood.
Read more »
To Win ‘Medicare for All,’ First Reclaim Medicare From ProfiteersEd Weisbart, MD, is a retired family physician in Olivette, Missouri, and board secretary of Physicians for a National Health Program.
Read more »
Medicare Advantage Is Denying More Requests for Seniors' Care: ReportMedicare Advantage, the privatized version of Medicare, serves a little more than half of all seniors on Medicare.
Read more »
Biden administration announces Medicare deal to lower costs of top drugsMedicare spent $50 billion covering the drugs last year.
Read more »
Deals struck to lower prices of Medicare’s costliest drugs, White House saysFederal officials reached deals with drug companies to lower the cost for 10 of Medicare’s costliest drugs, but shared few immediate details about the new price older Americans will pay.
Read more »